Deutsche Bank AG lessened its position in shares of argenx SE – (NASDAQ:ARGX) by 48.3% in the fourth quarter, HoldingsChannel.com reports. The firm owned 6,124 shares of the company’s stock after selling 5,727 shares during the quarter. Deutsche Bank AG’s holdings in argenx were worth $588,000 at the end of the most recent quarter.
A number of other large investors have also recently added to or reduced their stakes in ARGX. We Are One Seven LLC acquired a new stake in shares of argenx during the 4th quarter worth approximately $27,000. Partner Investment Management L.P. acquired a new stake in shares of argenx during the 4th quarter worth approximately $110,000. Dimensional Fund Advisors LP grew its position in shares of argenx by 19.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 9,074 shares of the company’s stock worth $872,000 after buying an additional 1,446 shares during the period. RTW Investments LP grew its position in shares of argenx by 7.2% during the 4th quarter. RTW Investments LP now owns 28,777 shares of the company’s stock worth $2,765,000 after buying an additional 1,924 shares during the period. Finally, Bank of America Corp DE grew its position in shares of argenx by 23.1% during the 4th quarter. Bank of America Corp DE now owns 10,247 shares of the company’s stock worth $984,000 after buying an additional 1,925 shares during the period. 63.62% of the stock is owned by institutional investors and hedge funds.
Shares of ARGX opened at $128.63 on Monday. argenx SE – has a 12-month low of $63.81 and a 12-month high of $135.58. The firm has a market capitalization of $4.14 billion, a P/E ratio of -54.74 and a beta of 1.12.
TRADEMARK VIOLATION NOTICE: This piece was first posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at https://www.baseballdailydigest.com/news/2019/05/20/argenx-se-argx-holdings-trimmed-by-deutsche-bank-ag.html.
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.
Further Reading: Fundamental Analysis and Individual Investors
Want to see what other hedge funds are holding ARGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for argenx SE – (NASDAQ:ARGX).
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.